Described herein are manufactured dietary supplements that contain a phospholipid extract, folic acid, vitamin D, vitamin B.sub.6, vitamin B.sub.12, Vitamin E, Vitamin C, iodine, iron, and magnesium. Described herein are manufactured dietary supplements that contain a phospholipid extract that contain phospholipid-DHA.

Described herein are manufactured dietary supplements that contain a phospholipid extract, folic acid, vitamin D, vitamin B.sub.6, vitamin B.sub.12, Vitamin E, Vitamin C, iodine, iron, and magnesium. Described herein are manufactured dietary supplements that contain a phospholipid extract that contain phospholipid-DHA.

The present embodiment relates to a composition containing human adipose stem cell-derived exosomes as an active ingredient for preventing, alleviating or treating liver fibrosis. The adipose stem cell-derived exosomes according to the present embodiment carry genetic information, protein, growth factor and the like for treating liver fibrosis, and have shown excellent results in treating liver fibrosis in animal models therefor, and, being a cell-derived substance, exosomes have the advantages of being highly biocompatible and having a superb absorption rate.

A composition for use in prevention, inhibition and/or treatment of coccidiosis in an animal is disclosed. The composition comprises an effective amount of Bidens pilosa, an active constituent thereof, or an active compound isolated therefrom. In another aspect, a composition for use in enhancing growth in an animal is disclosed. The composition comprising an animal feed and an effective amount of Bidens pilosa, or an isolated active constituent comprising a polyacetylenic compound.

A composition for use in prevention, inhibition and/or treatment of coccidiosis in an animal is disclosed. The composition comprises an effective amount of Bidens pilosa, an active constituent thereof, or an active compound isolated therefrom. In another aspect, a composition for use in enhancing growth in an animal is disclosed. The composition comprising an animal feed and an effective amount of Bidens pilosa, or an isolated active constituent comprising a polyacetylenic compound.

An oral formulation of bromelain effective to treat and prevent diarrhea caused by pathogenic microbes. This formulation does not kill pathogenic microbes, and thus does not facilitate the proliferation of anti-microbial resistant organisms. The invention entails formulating an aqueous oral suspension of bromelain, Blanose sodium carboxymethyl cellulose, citric acid anhydrous, Epikuron 135F lecithin oil and ethylenedinitrilotetraacetic acid, disodium salt dihydrate (“EDTA”).

An oral formulation of bromelain effective to treat and prevent diarrhea caused by pathogenic microbes. This formulation does not kill pathogenic microbes, and thus does not facilitate the proliferation of anti-microbial resistant organisms. The invention entails formulating an aqueous oral suspension of bromelain, Blanose sodium carboxymethyl cellulose, citric acid anhydrous, Epikuron 135F lecithin oil and ethylenedinitrilotetraacetic acid, disodium salt dihydrate (“EDTA”).

The present invention relates to synthetic nutritional compositions, especially infant formula compositions, with a low content of medium-chain fatty acids (or MFCAs) and particularly in specific proportions. The invention also relates to the use of said compositions to promote liver and/or gut maturation in infants or young children and/or to reduce the risk of liver and/or gut disease in infants or young children.

The present invention relates to synthetic nutritional compositions, especially infant formula compositions, with a low content of medium-chain fatty acids (or MFCAs) and particularly in specific proportions. The invention also relates to the use of said compositions to promote liver and/or gut maturation in infants or young children and/or to reduce the risk of liver and/or gut disease in infants or young children.

The present invention concerns a lactic composition useful for the prevention or treatment of diarrhea such as antibiotic associated diarrhea or “tourists.” The composition according to the invention contains at least a bacterial strain selected from the group consisting of Lactobacillus acidophilus, Lactobacillus acidophilus I-1492, Lactobacillus casei and a mixture of thereof.